SI0763534T1 - Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors - Google Patents

Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors

Info

Publication number
SI0763534T1
SI0763534T1 SI9630598T SI9630598T SI0763534T1 SI 0763534 T1 SI0763534 T1 SI 0763534T1 SI 9630598 T SI9630598 T SI 9630598T SI 9630598 T SI9630598 T SI 9630598T SI 0763534 T1 SI0763534 T1 SI 0763534T1
Authority
SI
Slovenia
Prior art keywords
phosphodiesterase
arylalkyl
inhibitors
hal
opt
Prior art date
Application number
SI9630598T
Other languages
English (en)
Slovenian (sl)
Inventor
Rochus Dr. Jonas
Michael Dr. Wolf
Norbert Dr. Beier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI0763534T1 publication Critical patent/SI0763534T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • C07D285/181,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polymerization Catalysts (AREA)
  • Saccharide Compounds (AREA)
SI9630598T 1995-09-14 1996-09-05 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors SI0763534T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19533975A DE19533975A1 (de) 1995-09-14 1995-09-14 Arylalkyl-diazinone
EP96114211A EP0763534B1 (de) 1995-09-14 1996-09-05 Arylalkyl-diazinone als Phosphodiesterase IV-Hemmer

Publications (1)

Publication Number Publication Date
SI0763534T1 true SI0763534T1 (en) 2003-10-31

Family

ID=7772083

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630598T SI0763534T1 (en) 1995-09-14 1996-09-05 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors

Country Status (24)

Country Link
US (1) US5859008A (cs)
EP (1) EP0763534B1 (cs)
JP (1) JP4149532B2 (cs)
KR (1) KR970015578A (cs)
CN (1) CN1110495C (cs)
AT (1) ATE233258T1 (cs)
AU (1) AU716113B2 (cs)
BR (1) BR9603736A (cs)
CA (1) CA2185397C (cs)
CZ (1) CZ286567B6 (cs)
DE (2) DE19533975A1 (cs)
DK (1) DK0763534T3 (cs)
ES (1) ES2192213T3 (cs)
HU (1) HUP9602511A3 (cs)
MX (1) MX9604020A (cs)
NO (1) NO309679B1 (cs)
PL (1) PL185961B1 (cs)
PT (1) PT763534E (cs)
RU (1) RU2167159C2 (cs)
SI (1) SI0763534T1 (cs)
SK (1) SK281474B6 (cs)
TW (1) TW363063B (cs)
UA (1) UA48946C2 (cs)
ZA (1) ZA967766B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
WO1999031090A1 (en) * 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
JP2002506856A (ja) * 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンpdeiii/iv阻害剤
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
CA2388121A1 (en) 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone derivatives as pde 4 inhibitors
CN1146562C (zh) 1999-10-25 2004-04-21 奥坦纳医药公司 作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
SK17052002A3 (sk) 2000-06-05 2003-12-02 Altana Pharma Ag Pyridazinónové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
WO2002072103A1 (en) * 2001-02-12 2002-09-19 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
AU2002317733B2 (en) 2001-04-25 2007-12-13 Altana Pharma Ag Phthalazinones derivatives useful as PDE4/7 inhibitors
EP1385838A1 (en) 2001-04-25 2004-02-04 ALTANA Pharma AG Piperazino-derivatives and their use as pde4 inhibitor
CA2453974C (en) * 2001-07-18 2011-01-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-(benzylideneamino)-3-(methylsulfanyl)-4h-1,2,4-triazin-5-one derivatives having a pde iv-inhibiting and tnf-antagonistic action for the treatment of heart diseases and allergies
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20040259863A1 (en) * 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
DE10227269A1 (de) * 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
US7220746B2 (en) 2002-08-10 2007-05-22 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors
CA2494650A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
US7494990B2 (en) 2004-02-04 2009-02-24 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788476A (fr) * 1971-09-08 1973-03-06 Sandoz Sa Nouveaux derives de la pyridazinone, leur preparation et leur application comme medicaments
DE3505609A1 (de) * 1985-02-19 1986-08-21 Merck Patent Gmbh, 6100 Darmstadt Benzimidazolyl-pyridazinone
AU614965B2 (en) * 1987-06-06 1991-09-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
DE3734083A1 (de) * 1987-10-08 1989-04-20 Heumann Pharma Gmbh & Co Benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
DE4134893A1 (de) * 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
DE4330915C1 (de) * 1993-09-11 1994-09-08 Steinel Bernhard Werkzeugmasch Palettenwechsler für Werkzeugmaschinen
DE19500558A1 (de) * 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone

Also Published As

Publication number Publication date
MX9604020A (es) 1997-03-29
KR100435301B1 (cs) 2004-09-07
CN1157287A (zh) 1997-08-20
SK281474B6 (sk) 2001-04-09
HUP9602511A2 (en) 1997-03-28
PL185961B1 (pl) 2003-09-30
UA48946C2 (uk) 2002-09-16
NO963852L (no) 1997-03-17
AU6551796A (en) 1997-03-20
US5859008A (en) 1999-01-12
HUP9602511A3 (en) 1998-04-28
CA2185397C (en) 2010-01-05
NO309679B1 (no) 2001-03-12
EP0763534A1 (de) 1997-03-19
NO963852D0 (no) 1996-09-13
SK110096A3 (en) 1997-08-06
DE19533975A1 (de) 1997-03-20
AU716113B2 (en) 2000-02-17
DE59610164D1 (de) 2003-04-03
JPH09124611A (ja) 1997-05-13
RU2167159C2 (ru) 2001-05-20
BR9603736A (pt) 1998-05-26
PT763534E (pt) 2003-07-31
CN1110495C (zh) 2003-06-04
CZ263096A3 (cs) 1998-03-18
DK0763534T3 (da) 2003-06-10
PL316070A1 (en) 1997-03-17
ES2192213T3 (es) 2003-10-01
TW363063B (en) 1999-07-01
KR970015578A (ko) 1997-04-28
ZA967766B (en) 1997-03-26
EP0763534B1 (de) 2003-02-26
HU9602511D0 (en) 1996-11-28
CZ286567B6 (cs) 2000-05-17
JP4149532B2 (ja) 2008-09-10
ATE233258T1 (de) 2003-03-15
CA2185397A1 (en) 1997-03-15

Similar Documents

Publication Publication Date Title
SI0763534T1 (en) Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors
AU1533692A (en) Quaternized panthenol compounds and their use
PT941082E (pt) Nova utilizacao para derivados de 1,3-propanodiol
ES2162617T3 (es) Nuevas 7-(sustituido)-8-(sustituido)-9-((glicilo sustituido)amido)-6-desmetil-6-desoxitetraciclinas.
HUT64945A (en) New 7-(substituted)-8-(substituted)-9-(substituted amino)-6-desmethyl-6-desoxy-tetracycline derivatives
ATE204269T1 (de) Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
MX9302169A (es) Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales.
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
SE8603099L (sv) Distamycinderivat och forfarande for deras framstellning
DK382089A (da) Benzamidderivater
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
GB8504072D0 (en) Cephem compounds
MX9206127A (es) Compuestos de acetileno
HU9602331D0 (en) Alkenyl-benzoyl-guanidine derivatives
GR3019893T3 (en) Novel S-adenosyl methionine decarboxylase inhibitors
AU3048592A (en) Substituted benzaldehyde derivatives
PH25911A (en) New cephem compounds pharmaceutical composition containing said compounds and method of use thereof
FI915653A0 (fi) 5-amino-5,6,7,8-tetrahydroquinoliner och beslaektade foereningar, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DE69702955D1 (de) Bis-Imide Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitung
DK439286A (da) Propanolderivater
SI9300625B (sl) N-substituirani derivati azabicikloheptana, njihova priprava in uporaba
FI951828A0 (fi) Imidatsopyridiinijohdokset ja menetelmä niiden valmistamiseksi
ATE99306T1 (de) Antagonisten von leukotrien d4.